Endostar plus pembrolizumab combined with a platinum-based dual chemotherapy regime for advanced pulmonary large-cell neuroendocrine carcinoma as a first-line treatment: A case report

Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare and highly aggressive cancer with a very poor prognosis. The proper treatment decision and possible prognosis outcome for advanced LCNEC is always an enormous challenge due to its scarcity. Here, we presented a 59-year-old male patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Sijia, Xiao, Yu, Chen, Leichong, Li, Zhenyu, Zong, Yan, Zhu, Kuikui, Meng, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202532/
https://www.ncbi.nlm.nih.gov/pubmed/35800072
http://dx.doi.org/10.1515/biol-2022-0062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202532/
https://www.ncbi.nlm.nih.gov/pubmed/35800072
http://dx.doi.org/10.1515/biol-2022-0062

Ejemplares similares